Do you want to read an article? Please log in or register.
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Related content
COMMENTED
Lipid-Lowering Drugs
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Eur Heart J.
Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG
doi: 10.1093/eurheartj/ehy334.
RECOMMENDED
Cardiovascular Risk and Diseases
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1016/j.jacc.2020.02.059.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
JAMA Cardiol.
Lloyd-Jones DM
doi: 10.1001/
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
Am Heart J.
De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED, TECOS Study Group.
doi: 10.1016/j.ahj.2019.11.005.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA.
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB
doi: 10.1001/jama.2019.16585.
Cardiovascular Risk and DiseasesHypertension
Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease
JAMA.
Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MS
doi: 10.1001/jama.2019.14120.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
Eur Heart J.
Penson PE, Long DL, Howard G, Toth PP, Muntner P, Howard VJ, Safford MM, Jones SR, Martin SS, Mazidi M, Catapano AL, Banach M
doi: 10.1093/eurheartj/ehy533.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial
JAMA Cardiol.
Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E
doi: 10.1001/jamacardio.
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
Cardiovasc Drugs Ther.
Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T
doi: 10.1007/